2.28
+0.13(+6.05%)
Currency In USD
Address
800 Saginaw Drive
Redwood City, CA 94063
United States of America
Phone
650 656 9323
Website
Sector
Healthcare
Industry
Biotechnology
Employees
155
First IPO Date
July 31, 2014
| Name | Title | Pay | Year Born |
| Dr. Laurent Fischer | President, Chief Executive Officer & Director | 1.12M | 1964 |
| Dr. Setareh Seyedkazemi Pharm.D. | Chief Development Officer | 705,621 | 1974 |
| Ms. Linda M. Rubinstein M.A. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 713,240 | 1967 |
| Mr. Kishor Peter Soparkar J.D. | Chief Operating Officer | 725,617 | 1971 |
| Dr. Rabia Gurses Ozden M.D. | Chief Medical Officer | 795,099 | 1969 |
| Ms. Carla Fiankan | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Dr. Romuald Corbau Ph.D. | Chief Scientific Officer | 0 | 1969 |
| Ms. Aneta Ferguson | General Counsel | 0 | N/A |
| Dr. R. Andrew Ramelmeier Ph.D. | Chief Technology Officer | 0 | 1962 |
| Ms. Dena House | Chief People Officer | 0 | N/A |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.